CREDO studies also show variation across state lines.
Half of the lowest priced generic medicines were priced at 1.24 (25th percentile) to 2.32 (75th percentile) times their international reference price, showing moderate variation in medicine price ratios across individual generic medicines in the PROAM sector.
Sensitivity analysis based on feedstock prices showed the sugarcane cost to be responsible for the greatest variation in the 1G + 2G MESP, as can be seen in Figure 8.
Prices showed a monthly rise of 0.1%.
The report shows variations among states.
Future net incomes depend on future timber prices, which show substantial temporal variation (Leskinen and Kangas 1998).
Prices of medicines show significant variation by therapeutic class of drugs and even within therapeutic classes across countries.
A decrease in negotiated drug prices occurred in this period was taken into account when comparing waste costs of the first vs the last six months of the year; in particular, all estimates were repeated as if prices didn't show any variation.
When repeating all estimates as if prices had not shown any variation (Table 3) we found that drug waste cost for cetixumab, docetaxel, gencitabine, pemetrexed and trastuzumab would have grown of 112, 94, 56, 1,130 and 364 euros, respectively, whereas that of oxaliplatin would have decreased, from 3,329 to 3,302 €.
Actual hospital prices for these products also showed price variations (between 160 and 190 Euro) among hospitals, but the actual prices were always lower than the list prices.
On the other hand, anxiolytics (low price) and atypical antipsychotics (high price) show homogeneous prices among areas with a coefficient of variation around 5%.
